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in Hodgkin's Disease Antigen CD30±Deficient Mice
Ryuichi Amakawa,*² Anne Hakem,*² TNF receptor (TNFR) molecules (Cleveland and Ihle,
1995; Gribskov et al., 1987). The CD30 gene is also foundThomas M. Kundig,² Toshifumi Matsuyama,*²
on the human chromosome 1p36 in close proximity toJohn J. L. Simard,* Emma Timms,*²
other TNFR superfamily members, such as TNFR2 andAndrew Wakeham,*² Hans-Willi Mittruecker,*²
OX40 (Fonatsch et al., 1992; Kemper et al., 1991; LatzaHenrik Griesser,² Hiroaki Takimoto,*²
et al., 1994).Rudolf Schmits,*² Arda Shahinian,*²
CD30 is expressed on virtually all H and RS cells andPamela S. Ohashi,² Josef M. Penninger,*²
on anaplastic large cell lymphomas (ALCLs) and is alsoand Tak W. Mak*²
expressed on some peripheral T cell lymphomas, adult T*Amgen Institute
cell leukemias/lymphomas, immunoblastic lymphomas,²Ontario Cancer Institute
and other non-HD lymphomas (Pallesen, 1990; Stein etDepartments of Medical Biophysics and Immunology
al., 1985; Suchi et al., 1987; Piris et al., 1990). CD30University of Toronto
expression is not limited to cells of hematopoietic origin.Toronto, Ontario
It is also found on various embryonal carcinomas, non-Canada M5G 2C1
embryonal carcinomas, malignant melanomas, and
mesenchymal tumors (Pallesen and Hamilton-Dutoit,
1988; Pallesen, 1990; Mechtersheimer and Moller, 1990).
Summary In addition, CD30 has been detected on CD81 and CD41
T cells from patients with human immunodeficiency vi-
CD30 is found on Reed±Sternberg cells of Hodgkin's rus (HIV) infection and on CD41 T cells from allergic
disease and on a variety of non-Hodgkin's lymphoma patients (Manetti et al., 1994; Maggi et al., 1994; Pizzolo
cells and is up-regulated on cells after Epstein±Barr et al., 1994; Del Prete et al., 1995). In vitro, CD30 is up-
virus, human T cell leukemia virus, and HIV infections. regulated on T and B lymphocytes after activation with
We report here that the thymus in CD30-deficient mice mitogen, on Epstein±Barr virus (EBV)-transformed B
contains elevated numbers of thymocytes. Activation- cells, and on human T cell leukemia virus I (HTLV-I)-
induced death of thymocytes after CD3 cross-linking and HTLV-II-transformedlymphocytes (Andreesen etal.,
is impaired both in vitro and in vivo. Breeding the CD30 1984; Stein et al., 1985; Schwarting et al., 1989; Ellis et
mutation separately into abTCR- or gdTCR-transgenic al., 1993).
mice revealed a gross defect in negative but not Histochemical staining of healthy tissues has shown
positive selection. Thus, like TNF-receptors and that CD30 expression is largely restricted to lymphoid
compartments, predominantly around B cell folliclesFas/Apo-1, the CD30 receptor is involved in cell death
and at the edge of germinal centers in lymph nodes andsignaling. It is also an important coreceptor that par-
spleen (Stein et al., 1985). CD30 is also found in theticipates in thymic deletion.
thymic medulla (Stein et al., 1985; Schuurman et al.,
1989). CD30 is not detected on cells of the peripheralIntroduction
blood or on resting lymphocytes (Ellis et al., 1993). A
ligand for CD30 (CD30L) has been cloned and found toCD30 was originally identified on mononucleated Hodg-
share sequence similarities with other members of thekin's (H) and multinucleated Reed±Sternberg (RS) cells
emerging TNF/NGF cytokine family (Smith et al., 1993).in Hodgkin's disease (HD) (Schwab et al., 1982; Stein et
There are few reports on tissue distribution of CD30L,al., 1982). Over the past decade, CD30 has also been
although it appears to be expressed on activated T cellsfound on malignant cells from numerous non-HD lym-
and macrophages (Smith et al., 1993; Gruss et al., 1994).phomas and other malignancies. It is also expressed on
Defective ligand±receptor systems involving the TNFR
some virus-infected cells. The presence of CD30 under
family of molecules are known to result in diseases. For
this broad range of pathological conditions has thus
example, mutations in theCD40L gene in humans results
suggested a role for CD30 in disease. in an X-linked immunodeficiencyhyper±immunoglobulin
CD30 is a 120 kDa type I cell surface glycoprotein M (IgM) syndrome (Aruffo et al., 1993; Korthauer et al.,
that also exists in some situations in the plasma as a 1993; DiSanto et al., 1993; Allen et al., 1993), and defects
soluble 84 kDa protein (Froese et al., 1987; Nawrocki in the Fas±Fas ligand system are implicated in autoim-
et al., 1988). The extracellular domain of CD30 shares mune disease in mice (Watanabe-Fukunaga et al., 1992;
sequence similarity with other tumor necrosis factor Lynch et al., 1994; Takahashi et al., 1994).
(TNF)/nerve growth factor (NGF) receptor superfamily In vitro studies have shown that CD30 can mediate a
members, including p55 and p75 TNF receptors, the low variety of activation and differentiation signals, a capac-
affinity NGF receptor, 4-1BB, OX40, CD27, CD40, and ity that varies with cell type and origin. Engagement of
the Fas/Apo-1 antigen (DuÈ rkop et al., 1992). All family CD30 on cell lines has been shown to induce immuno-
members are transmembrane proteins that contain ex- globulin secretion in EBV-transformed lymphoblastoid
tracellular cysteine-rich repeats (DuÈ rkop et al., 1992). cells, proliferation in T cell±like HD-derived cells, null
However, there is no sequence similarity in the cyto- response in B cell±like HD-derived cells, or cell death
plasmic region between CD30 and other TNF superfam- in ALCL cells (Smith et al., 1993; Gruss et al., 1994). In
ily members, and the cytoplasmic domain of CD30 does addition, different anti-CD30 antibodies with both ago-
nist and antagonist effects on CD301 cells have beennot appear to contain the death domain of Fas or other
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Table 1. Lymphocyte Numbers in Thymus, Spleen, and Lymph
Nodes from CD301/2 and CD302/2 Mice
Total Number of Lymphocytes (3 108)
Lymphatic Organ CD301/2 CD302/2
Thymus (n 5 8) 1.33 6 0.54 2.25 6 0.54 (p , 0.01)
Spleen (n 5 6) 0.78 6 0.15 0.79 6 0.11
Lymph nodes (n 5 4) 0.19 6 0.03 0.18 6 0.03
Total thymocytes, total spleen cells, and total mesenteric lymph
nodes cells were isolated and counted. Thymocyte numbers in
CD302/2 mice were significantly higher than those of CD301/2 mice.
Statistical analysis was done by Student's t test. The difference in
numbers of thymocytes was statistically significant (p , 0.01). All
mice used were 6- to 10-week-old littermates.
genomic clone isolated from a 129/J library. The 0.4
kb HindIII fragment containing the second-last exon of
the CD30 gene was replaced by a neomycin (neo)
gene cassette containing a poly(A) termination signal
(pMC1neo-polA), placed in an antisense orientation. The
linearized construct was introduced into E14K embry-
onic stem cells by electroporation, and G418-resistant
embryonic stem colonies were screened for homolo-
gous recombination by polymerase chain reaction
Figure 1. Generation of CD302/2 Mice
(PCR). Targeted clones obtained by PCR were con-
(A) Map of the partial CD30 locus (top), the targeting construct
firmed by genomic Southern blot analysis. The average(middle), and the targeted locus (bottom). A 7.2 kb genomic fragment
frequency of homologous recombination was about onewas used to construct the targeting vector. The 0.4 kb HindIII frag-
in 200 G418-resistant cells or one in 107 electroporatedment containing the second-last exon was replaced by a neo gene.
Primers specific for the neo gene and specific for an intronsequence cells. Four clones were chosen for injection into blasto-
59 of the targeting vector were used for PCR screening of embryonic cysts of C57BL/6 mice to generate mice carrying this
stem cell clones (arrows). CD30 flanking probe (probe A) was used CD302/2 mutation (Figure 1B). In an in vitro dish binding
to confirm the homologous recombination event.
assay, anti-CD3 monoclonal antibody (MAb)±activated(B) Southern blot analysis of representative mouse tail DNA. Geno-
T lymphocytes from CD302/2 mice did not bind mousemic DNA was digested with EcoRI and hybridized with probe A.
CD30Ls immobilized on a culture dish, indicating theSizes of fragments are indicated.
(C) Dish binding assay using mouse CD30L fused to the Fc portion absence of CD30 receptors in CD302/2 mice (Figure 1C).
of human IgG. Spleen cells stimulated with anti-CD3 antibody (clone The CD302/2 mice had no overt histological changes in
145 2C11) for 72 hr were cultured on a dish coated with mouse liver, kidney, spleen, lymph nodes, heart, or intestine.
CD30L fused to the Fc portion of human IgG using rabbit anti±human
IgG antibody. After 1 hr, the dishes were washed with PBS, and the
Peripheral T and B Cell Functionnumber of cells bound to immobilized CD30L was counted under
Lymph node, spleen, and bone marrow contained nor-six microscopic fields (4003). Mean values (6 SD) are shown for
one representative assay of three separate experiments. In addition, mal absolute numbers of cells (Table 1). Spleen and
CD30 surface expression was not detectable on CD302/2 T cells lymph nodes also contained normal ratios of Thy-1.21
after 5 days of in vitro activation. and B2201 cells, including expected numbers of CD41
and CD81 T cell subpopulations (Table 2). Thus, CD30
deficiency does not result in overt defects in homeosta-described. The observations that CD30 has pleiotropic
effects on different cells in vitro has made it difficult to sis in either B or T cell lineages. However, CD30 is up-
regulated on T cells after activation. We examined prolif-suggest a function for CD30 in vivo. Here we show that
mice deficient for CD30 expression after gene targeting erative responses of enriched T cells from lymph nodes
of CD30 mutant mice, which were similar to controlsmanifest a defect in thymocyte negative selection. Thus,
our data indicate that CD30 functions similarly to Fas after activation with anti-CD3 MAb, phorbol myristate
acetate (PMA)±calcium ionophore, or staphylococcaland TNFR in mediating cell death signals. While Fas and
TNFR operate mainly in mature T cells, CD30 appears to enterotoxin B (SEB) (Figure 2). The CD30 mutation also
did not have any effect on apoptotic cell death of periph-be the primary death-signaling molecule in thymocytes.
eral T lymphocytes in activation assays or after in vivo
stimulation with SEB (data not shown). In mature T cells,Results
CD30 does not appear to berequired for eitheractivation
or SEB-induceddeath signals throughthe Tcell receptorGeneration of Gene-Deficient Mice
To examine the physiological function of the HD-associ- (TCR).
The finding that a portion of CD45RO T cells expressesated molecule CD30, we generated a mouse line that
lacks CD30 expression by means of gene targeting (Fig- CD30 raised the possibility that CD30 might play a role in
T cell memory (Ellis et al., 1993). We therefore assessedure 1). The CD30 targeting vector (Figure 1A) was con-
structed from a 7.2 kb DNA fragment derived from a CD81 T cell memory in CD30-deficient mice. CD302/2 and
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Table 2. Lymphocytic Subsets in CD302/2 Mice
Percentage of Lymphocytes per Total Cells
Subsets CD301/1 CD301/2 CD302/2
Thymus
CD41CD81 81.6 6 4.0 80.8 6 6.2 78.9 6 4.7
CD41CD82 11.8 6 2.5 10.8 6 1.7 12.1 6 1.5
CD42CD81 3.3 6 0.7 3.0 6 1.1 3.4 6 0.9
Lymph nodes
Thy-1.21 B2202 79.9 6 5.9 82.1 6 1.9 82.4 6 4.3
Thy-1.22 B2201 10.6 6 3.5 9.3 6 1.2 9.8 6 0.9
CD41CD82 51.5 6 4.3 53.3 6 5.5 55.2 6 5.8
CD42CD81 21.7 6 0.9 22.1 6 1.5 23.5 6 2.2
Spleen
Thy-1.21 B2202 23.0 6 3.4 21.1 6 2.5 21.7 6 3.1
Thy-1.22 B2201 63.2 6 8.0 60.0 6 2.9 61.3 6 7.7
CD41CD82 20.2 6 3.2 17.7 6 0.9 18.1 6 2.9
CD42CD81 8.0 6 0.9 6.9 6 1.1 7.3 6 1.3
Cells from thymi, mesenteric lymph nodes, and spleens were collected and stained with anti-CD4 (PE) and anti-CD8 (FITC) or with anti-Thy-
1.2 (PE) and anti-B220 (FITC) and analyzed on a FACScan. Three mice were included in each group.
CD301/2 mice were injected intravenously with vesicular against this challenge infection (Bachmann and Kundig,
1994). VSV-immunized CD301/2 and CD302/2 mice werestomatitis virus (VSV). The predominant epitope for
CD81 cytotoxic T lymphocyte (CTL) in H-2b mice lies resistant to challenge infection, whereas nonimmunized
controls succumbed to vaccinia-induced meningitiswithin the nucleoprotein of VSV (Kundig et al., 1993b;
Puddington et al., 1986). Spleen cells were stimulated (data not shown). Thus, both in vitro and in vivo assays
indicated that CD81 CTL memory was unaltered in thein vitro 10 and 40 days after injection of virus with VSV
nucleoprotein (VSV-NP)-transfected antigen-presenting absence of CD30.
Basal serum levels for various subclasses of immuno-cells (Kundig et al., 1993a). In VSV-immune animals,
such restimulation generates CD81 VSV-NP-specific globulin (IgM, IgG1, IgG2a, IgG2b, and IgG3) were com-
parable for mutant and control mice (data not shown).CTL. Spleen cells from CD301/2 and CD302/2 mice gen-
erated similar cytotoxicity after restimulation (Figure 3A). In addition, we assessed humoral immune responses
after infection with VSV. This infection normally inducesThe biological relevance of this in vitro assay for memory
was confirmed in vivo, where mice were intracerebrally a rapid and T help±independent neutralizing IgM re-
sponse, followed by a T help±dependent IgG classchallenged at the same timepoints with vaccinia VSV-
NP recombinant virus (Binder and Kundig, 1991). VSV- switch (Bachmann and Kundig, 1994). Both IgM re-
sponses and class switching to IgG was similarly pres-specific CD81 memory CTL is required to protect mice
ent in CD302/2 and CD301/2 mice (Figure 3B).These data
indicate that, in the absence of CD30, B cell function and
responses are normal and T help for B cells is unim-
paired.
Thymus Is Enlarged in Mutant Mice
CD30 is expressed on small numbers of cells in the
thymic medulla (Stein et al., 1985), a thymic microenvi-
ronment where negative selection of thymocytes is
known to occur (Surh and Sprent, 1994; Sprent and
Webb, 1995). In addition, a recent study found CD30
mRNA expression to be abundant in the thymus (E. R.
Podack, personal communication). We therefore
searched for a defect in the thymus of CD302/2 mutant
mice. The thymi of CD302/2 mice showed normal T cellFigure 2. CD30-Deficient T Cells Proliferate Normally
subpopulations as defined by CD4 and CD8 expressionT cells were isolated from spleens using T cell enrichment columns.
(Table 2). However, the total number of thymocytes inEnriched T cells were plated in 96-well flat-bottomed plates at
1 3 105 cells per well and stimulated with PMA (15 ng/ml) plus mutant animals was elevated compared with littermates
calcium ionophore A23617 (250 ng/ml), SEB (2.5 mg/ml), and anti- (Table 1). To examine the possible impact of CD30 defi-
CD3 antibody (145 2C11) immobilized by goat anti±hamster immu- ciency on thymocyte survival, we cultured thymocytes
noglobulin. Syngeneic irradiated spleen cells were seeded as feeder in RPMI 1640 medium supplemented with 5% fetal calf
cells (5 3 105). After 3 days, cells were pulsed with 1 mCi of [3H]thymi-
serum (FCS). Cells from mutant animals showed similardine per well for 16 hr. Background counts without any stimulation
death rates up to 4 days. We then evaluated responseswere <1000 cpm. The data presented are from triplicate cultures (6
SD) and show one representative example of three experiments. of thymocytes to dexamethasone and g-irradiation, both
Cell
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Figure 3. Peripheral Immune Responses Are Unaltered in CD30-
Deficient Mice
(A) Secondary in vitro CD81 CTL responses are unaltered in the
absence of CD30. CD301/2 (closed circles) and CD302/2 (closed
triangles) mice were intravenously immunized with VSV or left un-
primed (open circles). After 10 days (left) and after 40 days (right),
spleen cells were restimulated in vitro with viral NP, and NP-specific
cytotoxicity was assessed on MC57 target cells infected with VSV.
Specific lysis of uninfected MC57 was less than 16% for all effectors
shown.
(B) Humoral immune response against VSV is unaltered in CD302/2
mice. CD301/2 (closed triangles) and CD302/2 (open triangles) mice
were intravenously immunized with VSV. Neutralizing serum IgM
titers were determined 4 days after immunization. Neutralizing se-
rum IgG was measured after 8 and 12 days. Titers in unprimed
control sera are not detectable.
Figure 4. Defect in Activation-Induced Death of Thymocytes
(A) Thymocytes (2 3 107) isolated from CD301/2 and CD302/2 mice
were cultured in RPMI 1640 media containing 5% FCS (control), 1
of which are known to cause rapid apoptotic death of
mM dexamethasone, or immobilized anti-CD3 antibody (10 mg/ml)
cortical double-positive (DP) (CD41CD81) thymocytes for 24 hr. As a control, thymocytes were cultured without any stimu-
(Sellins and Cohen, 1987; Wyllie, 1980; Scollay et al., lations for 24 hr. Viable cells were then counted using trypan blue
exclusion and double stained with anti-CD8±FITC and anti-CD4±PE1984), and found no difference in cell death between
MAbs. Viable cells (10,000) were analyzed using FACScan. Numbersmutant and control mice (Figure 4A). We further investi-
inside panels indicate relative percentages of positively stained cellsgated thymocyte responses to cross-linking with anti-
in each quadrant. Numbers above panels show total numbers of
CD3 antibodies, which are known to activate mature T viable cells after 24 hr of each treatment (Wallace et al., 1992).
cells but kill immature DP (CD41CD81) thymocytes in (B) DNA fragmentation of thymocytes following in vitro treatment
vitro (Smith et al., 1989) and in vivo (Shi et al., 1991). By with dexamethasone (1 mM) or anti-CD3 (10 mg/ml) for 24 hr. Each
lane represents DNA from 1 3 106 thymocytes. Control indicates24 hr after CD3 cross-linking in vitro, there were about
DNA from thymocytes cultured for 24 hr in RPMI 1640 media con-10-fold greater numbers of live thymocytes and an ap-
taining 5% FCS.proximately 25-fold increase of DP cells in mutant mice
as compared with controls (Figure 4A). A similar phe-
nomenon was seen 20 hr after anti-CD3 treatment in after anti-CD3 treatment in vitro were different in their
nucleosomal fragmentation pattern, which is character-vivo, where mutant animals showed 4-fold greater num-
bers of DP thymocytes compared with treated lit- istic of apoptosis (Figure 4B). Thus, it appears that DP
thymocytes from CD302/2 mice are less susceptible totermates (data not shown). In agreement with these find-
ings, DNA of thymocytes from control and CD302/2 mice anti-CD3-mediated apoptosis.
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Negative Selection in abTCR-Transgenic
CD302/2 Mice Is Defective
To investigate the role of CD30 in thymocyte apoptosis,
we bred the CD302/2 mutation into TCR-transgenic ani-
mals and examined selection processes in the thymus.
Treatment of normal thymocytes with anti-CD3 is
thought to mimic activation-induced cell death similar
to that observed with thymic deletion. Thus, our results
above pointed toward a possible defect in negative se-
lection. We hypothesized that defects in negative selec-
tion in CD30-deficient mice might only be subtly visible
owing to the small fraction of thymocytes that actually
undergoes negative selection processes (Table 1). To
increase the fraction of thymocytes subjected to nega-
tive selection, we bred the CD30 mutation into TCR-
transgenic mice with receptors specific for self-antigen.
An abTCR-transgenic mouse line specific for the male
antigen (H-Y) was bred with the CD302/2 mutant strain.
Thymocytes expressing the H-Y-specific transgenic
abTCRs are positively selected in female H-2b mice,
negatively selected in male H-2b mice, and nonselected
in H-2d mice (Teh et al., 1988; von Boehmer, 1990). Thy-
mocyte phenotypes were similar in positive-selecting
CD302/2 and CD301/2 mice, as defined by anti-CD4 and
anti-CD8 antibodies and staining for the transgenic TCR
Vb8.2 chain (Figure 5A). Thymocytes from these animals
also showed similar expression of heat-stable antigen
(HSA), CD69, Pgp-1, and the transgenic TCR Va chain
(data not shown). In nonselecting transgenic mice, there
were also no differences in thymocyte profiles between
CD302/2 and CD301/2 animals (data not shown).
Conversely, in negative-selecting male H-Y-trans-
genic mice, we observed a dramatic phenotype in
CD302/2 animals (Figure 5B). The negative-selecting
mice normally show a marked, absolute reduction of
thymocyte numbers as well as a proportionate decrease
in DP cells (Teh et al., 1988). In negatively selecting male
mice with CD302/2 mutations, the thymus contained an
approximately 20-fold increase in DP cells compared
with CD301/2 mice (Figure 5B; Table 3). However, there
is still about a 3- to 5-fold reduction in thymocyte num-
bers in CD302/2 mice compared with the thymi of posi-
tively selecting (H-2b) female mice (Table 3). Thus, these
data indicate that H-Y-transgenic CD302/2 mice have
only a partial, but clearly significant, defect in negative
selection in the thymus.
On the other hand, lymph nodes and spleen contained
similar numbers of lymphocytes in negatively selecting
CD302/2 and CD301/2 mice (Table 3). The number of T Figure 5. Clonal Deletion of H-Y TCR±Transgenic T Cells Is Defec-
tive in CD302/2 Micecells expressing the transgenic TCR Va chain detected
by the clonotypic MAb in these organs was also compa- (A) Thymocytes from CD301/2 and CD302/2 H-Y TCR±transgenic
mice in a positive-selecting background (H-2b female) were doublerable for both groups of mice (Table 3). To determine
stained with anti-CD8±FITC and anti-CD4±PE or anti-CD8±FITC andwhether transgenic T cells from male CD302/2 mice were
anti-Vb8±PE MAbs. Numbers indicate relative percentages of posi-autoreactive, we performed a syngeneic mixed lympho-
tive cells within a quadrant. Total numbers of thymocytes are also
cyte reaction (Figure 5C). Whereas transgenic T cells shown.
from female mice responded to the antigen, T cells from (B) Thymocytes from CD302/2 control mice and CD301/2 and CD302/2
lymph nodes of CD302/2 male mice did not proliferate H-Y TCR±transgenic mice in a negative-selecting background (H-2b
male) were double stained with anti-CD8±FITC and anti-CD4±PE or
anti-CD8±FITC and anti-Vb8±PE MAbs. Numbers indicate percent-
ages of positive cells within a quadrant. Total numbers of thymo-
cytes are also shown.M1/2), and CD302/2 H-Y TCR±transgenic mice in a negative-selecting
(C) Mixed lymphocyte culture of transgenic lymph node cells.Lymphbackground (H-2b male, M2/2) were incubated with 5 3 105 irradiated
node cells (5 3 105) from CD301/2 H-Y TCR±transgenic mice in a(2000 rads) spleen cells from syngeneic male mice. Hatched and
positive-selecting background (H-2b female, F1/2), CD301/2 H-Y TCR±stippled bars indicate proliferation of responder cells with or without
transgenic mice in a negative-selecting background (H-2b male,stimulator cells, respectively.
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Table 3. Profile of H-Y TCR Transgenic Model
Male Female
Tg2 CD301/2 Tg1 CD301/2 Tg1 CD302/2 TG1 CD302/2 Tg1 CD301/2 Tg1 CD302/2
Thymus (3 106) 101 12.6 39.2 41.4 110 160
CD41CD81 (%) 86.0 8.0 60.0 56.0 78.0 74.9
CD41CD81 (3106) 86.9 1.0 23.5 23.2 86.9 120
Mesenteric lymph node (3 106) 14.4 23.4 16.2 19.8 Ð Ð
T3.701 cells (%) 2.81 20.4 15.6 15.8 Ð Ð
Spleen (3 106) 24.0 25.8 47.5 25.8 Ð Ð
T3.701 cells (%) 1.73 6.93 3.23 7.03 Ð Ð
Total thymocytes, mesenteric lymph node cells, and spleen cells were isolated from a CD301/2 abTCR transgenic mouse in a negative-
selecting background (male, H-2b), and a control CD301/2 mouse. Total thymocytes were also isolated from CD301/2 and CD302/2 abTCR
transgenic mice with positively selecting backgrounds (female, H-2b). All mice were age matched. Cells were stained simultaneously with anti-
CD8 (FITC) and anti-CD4 (PE) or with anti-Thy-1.2 (PE) and clonotypic T3.70 antibody (rat IgG, supernatant), which recognizes the transgenic
TCR Va chain. T3.70 antibody was visualized using FITC-labeled goat anti±rat IgG (Southern Biotechnology Associates). In double-staining
experiments using T3.70, nonspecific staining due to remaining anti±rat immunoglobulin sites was blocked using 2 mg per 100 ml of rat IgG
(Sigma). Samples were analyzed using a FACScan. Results were expressed as a percentage of T3.701 cells among Thy-1.21 cells.
in response to g-irradiated spleen cells from male mice showed increased numbers of gd T cells in these organs
(Table 4). To examine the autoreactivity potential of thebearing the H-Y antigen. This suggested that the
transgenic T cells in the lymph nodes of CD302/2 mice gd T cells in CD302/2 mice, a mixed lymphocyte reaction
was carried out (Figure 6C). Proliferative responses ofwere not functionally autoreactive as determined by this
experimental approach. transgenic gd peripheral T cells isolated from positive-
selecting (H-2d/d)CD301/1 and CD302/2 mice after activa-
tion with spleen cells from negative-selecting CD302/2Defective Negative Selection in gdTCR-Transgenic
CD302/2 Mutant Mice mice (H-2b/b) were similar. In addition, stimulation with
allogeneic H-2b/b cells from negative-selecting CD302/2To evaluate further whether CD30 is required for thymic
negative selection of gd T cells, we bred a transgenic mice showed no proliferative responses for T cells de-
rived from spleen of negatively selecting CD302/2 andgdTCR (Vg2 Va11.3) (Dent et al., 1990) mouse strain with
CD302/2 mice. The gdTCR genes were originally cloned CD301/1 mice, suggesting that transgenic gd T cells in
the spleen of CD302/2 mice were not autoreactive.from a BALB/c (H-2d/d) nu/nu-derived T cell line with
alloreactivity against major histocompatibility complex
class I Tla molecules of H-2b/b mice (Bluestone et al.,
Deletion of Endogenous Superantigen
1988). In the H-2d/d mice, thymocytes undergo positive
Mls-2a±Responsive T Cells in CD302/2
selection mediated by H-2d/d class I molecules. In the Mice Is Not Impaired
negative-selecting H-2b/b mice, transgenic gd thymo-
To assess whether clonal deletion of thymocytes reac-
cytes are deleted, and fewer than 2% of thymocytes
tive to endogenous viral superantigens is also impaired
express a gdTCR (Dent et al., 1990).
in CD302/2 mice, we crossed CD302/2 mice with an A/J
Thymus phenotypes were similar in positively select-
mouse strain (H-2k/k) that expresses an endogenous viral
ing mice with CD302/2 and CD301/1 backgrounds (Fig-
superantigen, Mls-2a. Vb31CD41 and Vb111CD41 cells,
ure 6A). The numbers of gd T cells in spleen and lymph
both of which are reactive to Mls-2a, were efficiently
nodes were also comparable in positive-selecting mice
deleted in the thymus (data not shown) and the lymph
(data not shown). Thus, positive selection appeared nor-
nodes (Table 5) of both CD302/2 and CD301/2 mice. On
mal in gdTCR CD302/2 mice.
the other hand, CD41 cells carrying Vb61 or Vb141 recep-
Negative selection of transgenic gdTCR thymocytes,
tors, which do not recognize Mls-2a, were not deleted
however, was impaired in CD302/2 mice (Figure 6B). The
in these organs of CD302/2 and CD301/2 mice. These data
gdTCR-transgenic H-2b/b mice in CD301/1 backgrounds
indicate that CD30 is not essential for clonal deletion of
contained a small (z3 3 105) residual population of
T cells reactive to this endogenous viral superantigen.
gdTCR T cells in the thymus. The negative-selecting
mice with CD302/2 mutations, on the other hand, had
about 15-fold increased numbers (z5 3 106) of gdTCR Discussion
thymocytes. In these CD302/2 mice, over 95% of the
gdTCR1 thymocytes also expressed the activation Despite intensive investigation and the association of
CD30 with HD and other lymphomas, the cellular func-marker Pgp-1 (Figure 6B) (Skeen and Ziegler, 1993; Tat-
sumi et al., 1993). Taken together, the data from both tion of the CD30 molecule in vivo has remained a mys-
tery. Preactivated peripheral T cells and certain HD-gd- and abTCR-transgenic mice demonstrate that in the
absence of CD30 negative selection of thymocytes is derived cell lines (expressing T cell markers) have been
reported to show enhanced proliferation upon CD30partially impaired.
Although lymph nodes and spleens contained similar engagement (Smith et al., 1993; Gruss et al., 1994). We
found enriched T cells from CD30 mutant mice to havenumbers of lymphocytes in negatively selecting CD302/2
and CD301/1 mice, the thymi of CD302/2 mice were con- normal proliferative responses after anti-CD3 cross-link-
ing or treatment with mitogens. Spleen cells from mutantsistently severalfold larger. Moreover, the CD302/2 mice
Impaired Negative Selection in CD30-Deficient Mice
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mice immunized with VSV also generated normal cyto-
toxic responses in vitro, suggesting that proliferation
and effector functions of T cells were unimpaired. Thus,
although CD30 may have the ability to modulate T cell
proliferation in vitro, our data indicate that CD30 defi-
ciency does not cause a discernible defect in prolifera-
tion and effector functions of T lymphocytes.
EBV-immortalized B cell lines have been shown to
have enhanced immunoglobulin production and secre-
tion after cross-linking with anti-CD30 antibodies (Gruss
et al., 1994). CD30 has also been found on T helper cell
subsets that reportedly exhibit potent helper function
for immunoglobulin production (Alzona et al., 1994). In
CD30 mutant mice, basal serum immunoglobulin levels
and T helper±dependent IgG class switching against
VSV infection were normal, as were T helper±inde-
pendent IgM responses. As a result, there is no evidence
that CD30 is required in either maturation or class
switching of normal B cells. This does not preclude a
role for CD30, however, in malignant or transformed B
cells.
CD30 is expressed on a subset of T cells expressing
the isoform CD45RO (Ellis et al., 1993), considered to
be a marker of memory T cells (Merkenschlager and
Beverley, 1989). Our finding that both primary and sec-
ondary T cell responses were normal in CD30 mutant
mice demonstrates that CD30 is not essential in either
the production or maintenance (assessed up to 40 days)
of memory T cells.
Our findings in this report indicate that CD30 is a
surface receptor that influences the outcome of selec-
tion events in the thymus. This observation is consistent
with the finding that CD30 mRNA expression is mainly
found in the thymus (E. R. Podack, personal communica-
tion). It is interesting to note that, although we observed
a prominent role for CD30 in negative selection of thymo-
cytes, its expression in the thymus does not appear to
be extensive. It was reported that CD30 is present on
only small numbers of the so-called large cells in the
thymic medulla (Stein et al., 1985). A recent report also
shows that apoptotic cell death due to negative selec-
tion can be seen in only very few cells in the thymus
(Surh and Sprent, 1994). Thus, it is possible that CD30
is transiently expressed on thymocytes that aredestined
to die.
Significant numbers of male antigen±specific H-Y-
transgenic T cells are found in the periphery of nega-
tively selecting male mice with either CD301/1 or CD301/2
and anti-Pgp-1±PE MAbs. Numbers in histogram indicate percent-
ages of TCRVg2±positive cells. Numbers in panels indicate percent-
ages of positive cells in each quadrant. Total numbers of thymocytes
are shown.
Figure 6. Clonal Deletion of Transgenic gd T Cells Is Impaired in (C) Proliferative responses of spleen cells from gdTCR-transgenic
CD302/2 Mice mice were measured by [3H]thymidine incorporation after 3 days of
culture in a mixed lymphocyte reaction. Responder cells (5 3 105)(A) Thymocytes from CD301/2 control mice and CD301/2 and CD302/2
gdTCR-transgenic mice in a positive-selecting background (H-2d/d) from CD301/1 (d/d1/1) or CD302/2 (d/d2/2) gdTCR-transgenic mice
in a positive-selecting background (H-2d/d) and CD301/1 (b/b1/1) orwere stained with anti-gd±PE MAb. Numbers within histogram indi-
cate percentages of gdTCR-positive cells. Total numbers of thymo- CD302/2 (b/b2/2) gdTCR-transgenic mice in a negative-selecting
background (H-2b/b) were cultured with 5 3 105 irradiated (2000 rads)cytes are shown.
(B) Thymocytes from CD302/2 control mice and CD301/1 and CD302/2 spleen cells (H-2b/b) from CD302/2 gdTCR-transgenic mice in a nega-
tively selecting background (stippled bars). As controls, respondergdTCR-transgenic mice in a negative-selecting background (H-2b/b)
were stained with anti±TCR Vg2±FITC MAb or anti±pan gdTCR±FITC cells were cultured without stimulators (hatched bars).
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Table 4. Profile of gdTCR Transgenic Model (Negative Selection)
Thymus Mesenteric Lymph Nodes
Total Cell Number gdTCR1 Cells Total Cell Number gdTCR1/
Mice (3 106) gdTCR1 Cells (%) (3 106) (3 106) Thy-1.21 (%)
Litter 1
CD301/2 Tg2 114.0 2.4 2.7 41.0 0.9
CD301/2 Tg1 3.1 12.8 0.4 2.5 5.8
CD302/2 Tg1 9.9 49.8 4.9 4.1 42.0
Litter 2
CD301/2 Tg1 5.0 10.5 0.50 7.2 6.4
CD301/2 Tg1 16.0 53.5 8.6 4.0 69.0
Total thymocytes and mesenteric lymph node cells were isolated from CD301/2 and CD302/2 gdTCR transgenic (Tg) mice in negative-selecting
backgrounds (H-2b) and a control CD301/2 mouse (H-2b). Cells were stained with anti-gdTCR (PE) and anti-Thy-1.2 (FITC) antibodies and
analyzed on a FACScan. Two separate experiments are shown.
backgrounds. CD302/2 mice, however, showed no addi- thymus, while the interaction of bone marrow±derived
dendritic cells with autoreactive thymocytes probablytional elevation in the numbers of H-Y-specific T cells
mediates deletion (Sprent et al., 1988; Fowlkes and Par-in the periphery. When the Tlab-specific gdTCR mice
doll, 1989; Ramsdell and Fowlkes, 1990; Robey andwere examined, the numbers of transgenic TCR lympho-
Fowlkes, 1994; Schwartz, 1989). Thus, expression ofcytes in the thymus and lymph nodes were elevated in
CD30L on thymic dendritic cells might provide a meansCD302/2 mice compared with CD301/1 littermates. These
of mediating deletion of autoreactive thymocytes. It isdata suggested that the gd T cells were more likely to
noteworthy that bone marrow±derived macrophagesescape deletion in the CD302/2 mice. It should be noted
express CD30L (Smith et al., 1993). Alternatively, nega-that, in this model, few transgenic gdTCR T cells are
tive selection through CD30±CD30L binding might occurnormally found in the periphery of mice in the negative-
as a result of interactions between thymocytes. In thisselecting background (Dent et al., 1990). For both the
context, it is interesting that peripheral T cells activatednegative-selecting H-Y- and gdTCR-transgenic models,
with anti-CD3 antibodies or mitogens up-regulate bothtransgenic T cells from lymph nodes of CD302/2 mice
CD30 and CD30L (Smith et al., 1993).were shown to be functionally nonresponsive, indicating
Since CD30 is a TNFR family member, it was not sur-that, in addition to deletional mechanisms, other forms
prising that the molecule can be involved in mediatingof tolerance induction are operational in CD302/2 mice.
death signals. It is intriguing, however, that direct se-Curiously, while CD30 is important for clonal deletion
quence comparison showed no significant similaritiesof thymocytesreactive to antigens such as male H-Y and
between the CD30 cytoplasmic region and the newlyTlab antigens, CD30 is not required for clonal deletion of
defined TNFR family death domain, which is present inthymocytes reactive to the endogenous viral superanti-
TNFR p55, Fas antigen, the low affinity NGF receptor,gen, Mls-2a. In this context, it is interesting to note that,
ankyrin, MORT1, TRADD, MORT1/FADD, and RIPin the absence of gp39±CD40 interactions, negative se-
(Cleveland and Ihle, 1995). Although these TNFR mole-lection of Mls-reactive thymocytes is impaired (Foy et
cules all contain death domain homology, they appear toal., 1995). Thus, it is likely that the process of negative
mediate death signals with varying kinetics and throughselection may involve multiple, and to some extent re-
different mechanisms (Clement and Stamenkovic, 1994).dundant, costimulation signals.
In light of this, it is likely that CD30, with its highly uniqueThe differential expression of CD30L on thymic cells
cytoplasmic domain, might mediate death signalsmight determine whether positive or negative selection
through interactions with a novel protein(s).occurs during thymocyte development. Positive selec-
Fas plays a critical role in the deletion of mature pe-tion is thought to occur on the epithelial cells of the
ripheral T cells, but has no known role in negative selec-
tion in the thymus (Singer and Abbas, 1994). TNFR p55±
Table 5. TCR Vb Expression on Lymph Node Cells and TNFR p75±deficient mice also have normal thymic
from CD301/2 and CD302/2 Mice development (Pfeffer et al., 1993; Erickson et al., 1994;
Rothe et al., 1993), while p75 has been found to mediateCD30 Mls-2 Vb3 Vb11 Bb6 Vb14
death of mature CD81 T cells (Zheng et al., 1995). In our
1/2 a 0.2 0.2 9.4 9.2
CD30-deficient mice, quantitative analysis of T and B1/2 a 0.1 0.2 8.3 10.7
cells in peripheral lymph nodes and spleen, as well as1/2 b 3.6 8.2 7.3 6.9
examination in vivo of activation-induced cell death in2/2 a 0.1 0.1 9.8 5.0
2/2 a 0.3 0.1 9.0 6.2 response to SEB treatments, indirectly suggests that
2/2 b 3.1 6.7 8.8 7.2 peripheral tolerizing (selection) mechanisms are func-
tional. This is also consistent with the lack of overt dis-CD302/2 mice (H-2b/b, Mls-2b) were back-crossed into the A/J mouse
ease in these mice. By whatever mechanism CD30 in-strain (H-2k/k, Mls-2a). Lymph node cells and thymocytes from
6-week-old mice were stained simultaneously with FITC- or PE- duces deletion, it appears to have a unique function
conjugated antibodies to variable regions of the TCR and with PE- in death signaling during thymocyte ontogeny. Thus,
or FITC-conjugated anti-CD4 MAbs. Results are expressed as a different TNFR superfamily members appear to be dele-
percentage of Vb1 cells among CD4-positive T cells.
gated unique responsibilities in cell death signaling.
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of embryonic stem cells to the germline of chimeric mice was as-Although CD30 was initially described as a marker for
sessed by breeding with C57BL/6 mice and screening for agoutiHD lymphomas, observations in CD30 mutant mice have
offspring. Germline transmission of the CD30 mutation was con-so far provided no obvious explanations of the role of
firmed by Southern blot analysis of tail DNA, and mice heterozygous
CD30 in HD, ALCL, or other non-HD lymphomas and for the mutant gene were interbred to homozygosity. All mice used
malignancies. Our findings in CD30 mutant mice provide for experiments were 6±10 weeks of age.
no evidence that CD30 is required for proliferative sig-
Micenals. Rather, the results of this study indicate that, at
CD302/2 (H-2b) male mice were crossed with H-Y TCR (Va3 Vb8.2)least in the context of the thymus, CD30 is a cell death±
transgenic female mice (H-2d, CD301/1) (Teh et al., 1988; voninducing molecule. Thus, CD30 may not be involved in
Boehmer, 1990) or gdTCR (Va11.3Jd1Cd/Vg2Jg1Cg1) transgenic fe-
tumor formation, or may even retard lymphoma develop- male mice (H-2d, CD301/1) (Dent et al., 1990; Bluestone et al., 1988).
ment. This latter suggestion might be consistent with F1 mice (H-2b/d, CD301/2) carrying either H-Y- or gd-transgenic TCRs
the observation that HD is a relatively slow-growing lym- were inter-crossed to obtain the H-Y- or gdTCR-transgenic mice in
appropriate backgrounds. Typing of mice for TCR transgenes wasphoma. On the other hand, one may speculate that mu-
carried out by staining peripheral blood lymphocytes with anti-Vb8tations in the CD30 gene or alteration of its expression
MAb (phycoerythrin [PE] conjugated) and anti-Thy-1.2 MAb (fluores-(or other proteins participating in its signaling pathway)
cein isothiocyanate [FITC] labeled) for H-Y-transgenic mice or with
might interfere with cell death, conferring growth advan- anti-gdTCR MAb (PE conjugated) and anti-Thy-1.2 MAb (FITC la-
tage to premalignant cells, perhaps leading to tumor beled) for gdTCR-transgenic mice. All mice were bred in the animal
progression. Thus, it is of interest that patients with facilities of the Ontario Cancer Institute. Care of animals was in
accordance with guidelines of the Medical Research Council ofHD can exhibit elevated levels of soluble CD30 in their
Canada.plasma (Pizzolo et al., 1990; Gause et al., 1991).
Finally, CD30 cross-linking has recently been found
Dish Binding Assayto induce activation of the NF-kB transcription factor
Lymph node cells collected from CD301/1, CD301/2, and CD302/2
(McDonald et al., 1995), which is recognized as a trans- mice were stimulated in HL-1medium (HycorBiomedical) containing
activator involved in myriad signaling pathways, includ- 2% FCS with anti-CD3 antibody (145 2C11; Pharmingen) immobi-
lized on the culture dishes using goat anti±hamster IgG antibodying those regulating growth and proliferation. It is quite
(Jackson Immunoresearch). After 72 hr, cells were washed threepossible that CD30 can provide either death or activation
times with phosphate-buffered saline (PBS) and then used for dishsignals depending on the cell type and developmental
binding assay. Center portions of plates (1008; Falcon) were coated
stage of the cell. with 70 ml of rabbit anti±human IgG antibody (10 mg/ml; Southern
Biotechnology Associates) for 2 hr at room temperature. Plates were
washed three times with PBS and then incubated with 3 ml of PBSExperimental Procedures
containing 1% bovine serum albumin (BSA) for 14 hr at 48C. Plates
were washed once with PBS and incubated for 1 hr at room tempera-
Cells ture with 400 ml of HL-1 medium containing 2% FCS and 2.5 mg/ml
E14K embryonic stem cells from 129/Ola mice were maintained of mouse CD30L fused to the Fc portion of human IgG (CD30L±Fc;
on a layer of mitomycin C±treated embryonic fibroblasts in culture provided by Dr. C. Smith). For controls, plates were incubated in
medium (Dulbecco's modified Eagle's medium) supplemented wih HL-1, 2% FCS medium without CD30L±Fc. Plates were then washed
leukemia inhibitory factor, 15% FCS, L-glutamine, and b-mercapto- twice with PBS. Lymph node cells (2 3 106) activated with anti-CD3
ethanol. antibody as described above were cultured in these plates in HL-1
medium containing 2% FCS at 378C for 1 hr. Plates were finally
washed three times with PBS, and the number of cells bound toGeneration of CD302/2 Mutant Mice
the center portions coated with CD30L±Fc was counted for threeMurine cDNA for CD30 was cloned from a mouse T cell cDNA library
different microscopic fields (4003).in lZapII (Stratagene) using the human CD30 cDNA (DuÈ rkop et al.,
1992) (provided by Dr. H. Stein). The CD30 cDNA clone was partially
Flow Cytometric Analysissequenced and used for screening a mouse genomic library (partial
The following MAbs (all obtained from Pharmingen) were used: anti-MboI digest of 129/J genomic DNA in lDASH phage vectors). Geno-
CD4 (FITC labeled or PE conjugated), anti-CD8 (FITC or PE labeled),mic clones were mapped and partially sequenced. A 7.2 kb genomic
anti-B220 (FITC labeled), anti-Thy-1.2 (FITC or PE labeled), anti-gdfragment (gCD30) containing two exons of the CD30 gene was used
(PE conjugated), anti-Vb3 (PE conjugated), anti-Vb6 (FITC labeled),to construct the targeting vector. A 0.4 kb genomic HindIII fragment
anti-Vb8 (PE conjugated), anti-Vb11(FITC labeled), anti-Vb14 (FITCcontaining the second-last exon was replaced with a neo resistance
labeled), anti-Vg2 (FITC labeled), anti-H-2Kb (FITC labeled), anti-gene cassette, pMC1neo-polA (Thomas and Capecchi, 1987) to ob-
H-2Kd (PE conjugated), and anti-Pgp-1 (PE conjugated). Blood sam-tain the targeting vector TV30neoA. The neo resistance gene was
ples (20 ml) were collected in heparinized capillary tubesand washedinserted in antisense orientation to the CD30 transcriptional orienta-
once in immunofluorescence staining buffer (PBS, 1% BSA, 0.1%tion and contained a polyadenylation signal (Figure 1A). E14 embry-
NaN3). Single cell suspensions from thymocytes, spleen cells, lymphonic stem cells (5 3 106) were electroporated with 20 mg of linearized
node cells, and bone marrow cells from 6- to 10-week-old micetargeting vector TV30neoA DNA (340 V, 250 mF; Bio-Rad Gene
were prepared as described previously (Wallace et al., 1992), resus-Pulser). G418 (300 mg/ml) selection was started 48 hr after transfec-
pended in PBS, and incubated with appropriate MAbs for 30 mintion, and G418-resistant colonies were obtained after 10 days. PCR
at 48C. Stained cells were analyzed using a FACScan flow cytometerscreening for homologous recombination was carried out as de-
(Becton±Dickinson).scribed previously (Fung-Leung et al., 1991). A primer specific for
the neo resistance gene (59-TATCAGGACATAGCGTTGGC-39) and
an outside primer specific for the CD30 gene (59-CAACCCTGGCTGA T Cell Stimulation Assay
T cells were isolated from spleens and lymph nodes of CD301/2 andGTTACTCTACCC-39) upstream of the construct were used in PCR.
Homologous recombination was subsequently confirmed by EcoRI CD302/2 mice using columns to negatively enrich for T cells (R&D
Systems). Purified T cells (1 3 105) were placed into flat-bottomeddigestion of genomic DNA and hybridization with probe A (Figure
1A). Chimeric mice were produced by injection of embryonic cells 96-well plates containing 5 3 105 irradiated (2000 rads) splenic
feeder cells and freshly prepared Iscove's modified Dulbecco's me-into 3.5-day-old blastocysts as described previously (Caligariscap-
pio et al., 1995; Thomas and Capecchi, 1987; Fung-Leung et al., dium (10% FCS, 1025 M b-mercaptoethanol). Optimal concentrations
of PMA±calcium ionophore (250 ng/ml calcium ionophore and 12.51991; Bradley et al., 1984; Thompson et al., 1989). The contribution
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ng/ml PMA) and SEB (10 mg/ml) were added. For TCR±CD3 cross- energetic assistance. R. A and T. W. M were supported by fellow-
ships from the Medical Research Council (MRC) of Canada. Theselinking, plates were coated overnight at 48C with 10 mg per well of
goat anti±hamster immunoglobulin and subsequently with anti± studies were supported by the MRC and by the National Cancer
Institute of Canada.mouse CD3e (1452C11 hamster IgG; Pharmingen) at 378C for 2 hr. To
remove unbound antibodies, plates were washed with PBS before
Received September 12, 1995; revised January 11, 1996.incubation of T cells. T cells were harvested at day 3 after a 16 hr
pulse with 1 mCi of [3H]thymidine per well. [3H]thymidine uptake was
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